PRPrakash Ramachandran

Prakash Ramachandran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prakash Ramachandran has a total of 507 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hepatic stellate cells remodel liver-resident CD8+ T cells and constrain immunosurveillance

    by George E. Finney, Daniel Brown Romero, Bethany H. James, Scott P. Davies, Stephanie Kucykowicz, Anandita Mathur, Keshav Rao, Ginevra Pistocchi, Kexin Kong, Jacky Tam, et al.

    The liver constitutes a distinct immunological niche in which CD8+ T cells balance immune protection and tissue integrity. How chronic liver disease (CLD) remodels human liver–resident CD8+ T cells remains poorly understood. We demonstrate that activated hepatic stellate cells (HSCs) create immunoinstructive fibrotic niches that regulate liver-resident CD8+ T cell differentiation, localization, and function. CD103-expressing liver-resident CD8+ T cells accumulate with increasing fibrosis severity and preferentially localize within collagen-rich scar tissue. HSC-derived and matrix-retained TGFβ promote acquisition of a residency program characterized by upregulation of CD103, ECM-binding integrins, and adhesion molecules. Despite their increased abundance, liver-resident CD8+ T cells in CLD exhibit impaired antigen-dependent effector function, increased inhibitory receptor expression, and a transcriptional program associated with T cell dysfunction. Importantly, responses to PMA/ionomycin remain intact, indicating preserved effector competence. Mechanistically, HSCs directly suppress antigen-specific liver-resident CD8+ T cell function, with partial restoration following PD-L1/PD-L2 blockade. These findings identify the fibrotic niche as a central regulator of liver-resident CD8+ T cells and reveal how fibrosis can limit local immunosurveillance.

  • Open Access

    A human single-cell atlas identifies OLR1+ scar-associated macrophages as a potential therapeutic target for chronic liver disease

    by Eleni Papachristoforou, Kexin Kong, Fabio Colella, Jacky Tam, Juliet Luft, Ravi Parhar, Yingxin Liang, Ailish McCafferty-Brown, George Finney, Keshav Rao, et al.

    Chronic liver disease (CLD) results in liver fibrosis, leading to adverse clinical outcomes. Macrophages regulate fibrosis and represent an attractive therapeutic target. However, the specific macrophage subpopulation that drives fibrosis in CLD remains unclear. Here we generate a liver single-cell atlas comprising 649,295 cells from 42 healthy and 35 CLD patients, identifying 125 transcriptionally distinct cellular states. We resolve two types of disease-expanded TREM2 + scar-associated macrophages (SAMac), including a pro-inflammatory subpopulation that expresses the scavenger receptor OLR1 and spatially accumulates in the CLD fibrotic niche. High hepatic OLR1 expression was associated with increased fibrosis across multiple CLD etiologies and adverse patient outcomes in metabolic dysfunction-associated steatotic liver disease. Corollary pro-inflammatory OLR1 + SAMac expanded in mouse CLD, while targeting of macrophage OLR1 attenuated fibrogenic activity in human coculture and multilineage spheroid models. Overall, our atlas provides a reference to study disease-associated cell states in CLD and identifies OLR1 as a potential therapeutic target to attenuate liver fibrosis.


  • Open Access

    Regression of liver cirrhosis

    by Jonathan Andrew Fallowfield, Prakash Ramachandran, Timothy James Kendall


  • Open Access

    Gallstones: a driver of cardiovascular disease? A triangulation study

    by Cameron J Fairfield, Thomas Drake, Riinu Pius, William A Cambridge, David W Clark, Lydia Charlotte Cullen, Jonathan Andrew Fallowfield, Caroline Hayward, Neil C Henderson, Andrii Iakovliev, et al.

    Objective: Gallstone carriers have elevated cardiovascular disease (CVD) risk. Shared lifestyle risk factors only partly explain the observed association. Gallstone-driven inflammation may contribute to CVD with cholecystectomy offering protection. A triangulation study using observational, genetic and interventional data was undertaken. Design: Cox proportional hazards analysis of UK Biobank data assessed 10-year CVD risk in gallstone cases versus healthy controls and gallstone carriers versus post-cholecystectomy individuals. Data were meta-analysed with other published cohorts. Gallstone state was additionally modelled as a time-varying covariate with states: gallstone-free, gallstone-carrier, gallstone-related inflammation and post cholecystectomy. Finally, Mendelian randomisation (MR) analyses were undertaken using 41 gallstone-promoting single nucleotide polymorphisms (SNPs) to assess causal effects of gallstones on CVD. Results: In UK Biobank (gallstones=32,528, controls=424,520) and meta-analysis (gallstones=202,055, controls=1,256,861), gallstones were associated with CVD (adjusted HR (aHR) 1·28 (1·20 to 1·36), meta-analysis aHR 1·23 (1·18 to 1·29)). Cholecystectomy was associated with reduced CVD risk compared with gallstone carriers (aHR 0·71 (0·62 to 0·82)). Time-varying analysis supported elevated CVD risk with inflammation and reduced CVD following cholecystectomy. MR analyses required handling of pleiotropic cholesterol-lowering SNPs that affect CVD risk independently of gallstones. Multivariable MR adjusting for the impact of SNPs on lipids showed no significant association of CVD and gallstones. Conclusion: Gallstones are associated with elevated CVD risk, which increased with gallstone-related inflammation but diminished post cholecystectomy. The benefits of cholecystectomy indicate a potential causal pathway. However, as cholecystectomy interrupts exposure to gallstones, the effects of gallstone-promoting SNPs on CVD are likely attenuated by cholecystectomy, meaning MR analyses cannot detect an underlying causal effect.

  • Open Access

    A Human Single-cell Atlas Identifies OLR1+ Scar-associated Macrophages as a Therapeutic Target for Chronic Liver Disease

    by Eleni Papachristoforou, Kexin Kong, Fabio Colella, Jacky Tam, Juliet Luft, Elena F. Sutherland, Stefan Veizades, Malgorzata Grzelka, Pak Kwan Qiu, Ayma Asif, et al.

    Chronic liver disease (CLD) is a major global healthcare problem. Irrespective of cause, chronic damage to the liver results in fibrosis, which is associated with adverse clinical outcomes. Immune cells, in particular monocyte-derived macrophages (MDMs), are key regulators of fibrosis and represent an attractive therapeutic target for CLD. However, it has remained unclear which specific subpopulation of MDMs drives pro-inflammatory and pro-fibrotic functions in human CLD and how they might be selectively modulated. Here, we generate an annotated human liver single cell atlas from 42 healthy and 35 CLD patients, identifying 125 transcriptionally distinct cellular states. Leveraging large patient and cell numbers, our atlas resolves rare liver cell states and distinguishes two types of disease-expanded scar-associated macrophages (SAMac), including a specific subpopulation with a pro-inflammatory pro-fibrotic phenotype. The scavenger receptor OLR1 was enriched in pro-inflammatory SAMacs and high hepatic OLR1 expression was associated with increased mortality in CLD patients. A corresponding monocyte-derived OLR1+ SAMac subpopulation expanded in a mouse model of CLD and exhibited a pro-inflammatory phenotype based on single-cell RNA-seq, single-cell ATAC-seq, and flow cytometry analyses. Primary human OLR1+ MDMs promoted fibrogenic signalling in multilineage liver spheroid cultures, whilst specific targeting of OLR1 reduced IL-1β production by human macrophages and attenuated myofibroblast activation. Overall, our annotated human liver single-cell atlas provides a valuable reference to study disease-associated cell states in CLD. We utilise this resource to identify a distinct pro-inflammatory subpopulation of SAMacs and highlight OLR1 as a potential therapeutic target to specifically modulate SAMac function and attenuate liver fibrosis.